Loading...
Loading...
ITRM| Name | Value |
|---|---|
| Revenues | 2.6M |
| Cost of Revenue | 0.4M |
| Gross Profit | 2.2M |
| Operating Expense | 11.0M |
| Operating I/L | -11.4M |
| Other Income/Expense | -0.8M |
| Interest Income | 0.0M |
| Pretax | -12.2M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -12.4M |
Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing and commercializing anti-infective drugs. Its primary product in development is sulopenem, a novel anti-infective compound available in oral and IV formulations. Sulopenem is currently in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company generates revenue through the development and eventual commercialization of these anti-infective drugs, targeting a range of infectious diseases.
